Cell & gene therapies (CGT), such as CAR T-cells, are life-saving personalized medicines, but their production remains extremely challenging and expensive, limiting patient access. Limula SA provides a platform enabling cell therapy manufacturing at scale. Combined with Limula's expertise, this unique tool supports biotech companies with CGT assets, or CDMO with CGT customers, at all stages of the product life cycle, from pre-clinical R&D to patient batch production for clinical use.